Commentary on: Adipose-Derived Stem Cells in Aesthetic Surgery: A Mixed Methods Evaluation of the Current Clinical Trial, Intellectual Property, and Regulatory Landscape

Commentary on: Adipose-Derived Stem Cells in Aesthetic Surgery: A Mixed Methods Evaluation of the... Research Aesthetic Surgery Journal Commentary 2018, Vol 38(2) 211 © 2017 The American Society for Aesthetic Plastic Surgery, Inc. Commentary on: Adipose-Derived Stem Reprints and permission: journals.permissions@oup.com Cells in Aesthetic Surgery: A Mixed Methods DOI: 10.1093/asj/sjx177 www.aestheticsurgeryjournal.com Evaluation of the Current Clinical Trial, Intellectual Property, and Regulatory Landscape Afshin Mosahebi, MBBS, FRCS, MBA, PhD, FRCS (Plast) Editorial Decision date: September 1, 2017; online publish-ahead-of-print October 31, 2017. Adipose-derived stem cells (ADSC) continue to incite con- Disclosures troversy in the medical profession, are highly sought after The author declared no potential conflicts of interest with by the public, incite excitement in commercial companies, respect to the research, authorship, and publication of this and are seen as a lucrative income generator in clinics. article. This interesting analysis of ADSC registered trials as well Funding as registered intellectual properties further illustrates these points. The author received no financial support for the research, The article confirms the paucity of good quality trials, authorship, and publication of this article. despite 1250 registered ones, almost none seem to plan long-term follow up of the effect. Additionally, there is no REFERENCE agreed standard methodology of assessment of the quality 1. Arshad Z, Halioua-Haubold CL, Roberts M, et al. Adipose- of the ADSC. This is in spite of the large number of patents Derived Stem Cells in Aesthetic Surgery: A Mixed Methods put in for separation and concentration technologies, as Evaluation of the Current Clinical Trial, Intellectual well as innovative applications. Property, and Regulatory Landscape. Aesthet Surg J. The explanation of regulatory landscape is very enlight- 2018;38(2):199–210. ening, illustrating the great deal of variability in different continents. In some cases, vagueness and lack of clarity in regulation has enabled potential unscrupulous misin- terpretations and misuses false promotion of services. An exemplar regulation is in Japan, where there is a specific section for regenerative medicine. This not only helps to promote innovation and genuine effect and uses, but also reduces the back-street rogue clinics and should be Prof Mosahebi is a Consultant Plastic Surgeon, Department of Plastic Surgery, Royal Free Hospital, London, United Kingdom. a lesson to regulatory bodies in the United States and European Union. Corresponding Author: This unique article gives ASJ readers a comprehensive Prof Afshin Mosahebi, Department of Plastic Surgery, Royal Free overview of global landscape in ADSC field, trials, and Hospital, NW3 2QG London, United Kingdom. E-mail: a.mosahebi@ucl.ac.uk regulation. Downloaded from https://academic.oup.com/asj/article-abstract/38/2/211/4583508 by Ed 'DeepDyve' Gillespie user on 16 March 2018 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Aesthetic Surgery Journal Oxford University Press

Commentary on: Adipose-Derived Stem Cells in Aesthetic Surgery: A Mixed Methods Evaluation of the Current Clinical Trial, Intellectual Property, and Regulatory Landscape

Free
1 page

Loading next page...
1 Page
 
/lp/ou_press/commentary-on-adipose-derived-stem-cells-in-aesthetic-surgery-a-mixed-McGNozva05
Publisher
Mosby Inc.
Copyright
© 2017 The American Society for Aesthetic Plastic Surgery, Inc. Reprints and permission: journals.permissions@oup.com
ISSN
1090-820X
eISSN
1527-330X
D.O.I.
10.1093/asj/sjx177
Publisher site
See Article on Publisher Site

Abstract

Research Aesthetic Surgery Journal Commentary 2018, Vol 38(2) 211 © 2017 The American Society for Aesthetic Plastic Surgery, Inc. Commentary on: Adipose-Derived Stem Reprints and permission: journals.permissions@oup.com Cells in Aesthetic Surgery: A Mixed Methods DOI: 10.1093/asj/sjx177 www.aestheticsurgeryjournal.com Evaluation of the Current Clinical Trial, Intellectual Property, and Regulatory Landscape Afshin Mosahebi, MBBS, FRCS, MBA, PhD, FRCS (Plast) Editorial Decision date: September 1, 2017; online publish-ahead-of-print October 31, 2017. Adipose-derived stem cells (ADSC) continue to incite con- Disclosures troversy in the medical profession, are highly sought after The author declared no potential conflicts of interest with by the public, incite excitement in commercial companies, respect to the research, authorship, and publication of this and are seen as a lucrative income generator in clinics. article. This interesting analysis of ADSC registered trials as well Funding as registered intellectual properties further illustrates these points. The author received no financial support for the research, The article confirms the paucity of good quality trials, authorship, and publication of this article. despite 1250 registered ones, almost none seem to plan long-term follow up of the effect. Additionally, there is no REFERENCE agreed standard methodology of assessment of the quality 1. Arshad Z, Halioua-Haubold CL, Roberts M, et al. Adipose- of the ADSC. This is in spite of the large number of patents Derived Stem Cells in Aesthetic Surgery: A Mixed Methods put in for separation and concentration technologies, as Evaluation of the Current Clinical Trial, Intellectual well as innovative applications. Property, and Regulatory Landscape. Aesthet Surg J. The explanation of regulatory landscape is very enlight- 2018;38(2):199–210. ening, illustrating the great deal of variability in different continents. In some cases, vagueness and lack of clarity in regulation has enabled potential unscrupulous misin- terpretations and misuses false promotion of services. An exemplar regulation is in Japan, where there is a specific section for regenerative medicine. This not only helps to promote innovation and genuine effect and uses, but also reduces the back-street rogue clinics and should be Prof Mosahebi is a Consultant Plastic Surgeon, Department of Plastic Surgery, Royal Free Hospital, London, United Kingdom. a lesson to regulatory bodies in the United States and European Union. Corresponding Author: This unique article gives ASJ readers a comprehensive Prof Afshin Mosahebi, Department of Plastic Surgery, Royal Free overview of global landscape in ADSC field, trials, and Hospital, NW3 2QG London, United Kingdom. E-mail: a.mosahebi@ucl.ac.uk regulation. Downloaded from https://academic.oup.com/asj/article-abstract/38/2/211/4583508 by Ed 'DeepDyve' Gillespie user on 16 March 2018

Journal

Aesthetic Surgery JournalOxford University Press

Published: Feb 1, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial